Addendum

Cipaglucosidase alfa (Pompe disease) – Addendum to Project A23-79

Report documents

Indication:

Adults with late-onset Pompe disease (LOPD) (acid α-glucosidase [GAA] deficiency)

Result of dossier assessment:

After addendum now: indication of minor added benefit

2024-02-01 A G-BA decision was published.

Project no.: A23-133
Commission: Commission awarded on 12.12.2023 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Digestion, metabolism and hormones
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI: https://dx.doi.org/10.60584/A23-133

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.